Impact of glycoprotein B genotype and naturally occurring ORF UL56 polymorphisms upon susceptibility of clinical human cytomegalovirus isolates to letermovir

Peter Lischka, Douglas Zhang, Daniel Holder, Holger Zimmermann

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Letermovir is a novel anti-HCMV drug in Phase III development that targets the UL56 subunit of the viral terminase complex. In immunocompromised patients four major glycoprotein B (gB) subtypes are known and may influence pathogenesis and thus disease outcomes. Using a panel of 74 letermovir-naïve, low-passage, clinical HCMV isolates, we examined the potential impact of i) gB genotype and ii) naturally occurring UL56 sequence variations upon susceptibility to letermovir. Our data show that letermovir's potency is independent of gB subtype and show that naturally-occurring letermovir-resistance is rare or possibly absent.

Original languageEnglish
Pages (from-to)204-209
Number of pages6
JournalAntiviral Research
Volume132
DOIs
StatePublished - Aug 1 2016

Bibliographical note

Publisher Copyright:
© 2016 Elsevier B.V.

ASJC Scopus subject areas

  • Pharmacology
  • Virology

Fingerprint

Dive into the research topics of 'Impact of glycoprotein B genotype and naturally occurring ORF UL56 polymorphisms upon susceptibility of clinical human cytomegalovirus isolates to letermovir'. Together they form a unique fingerprint.

Cite this